Press releases

21 Dec 2021

Disposals of own shares

16 Dec 2021

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial

10 Dec 2021

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

3 Dec 2021

Disposals of own shares

3 Dec 2021

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care

2 Dec 2021

UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease

Press releases

Press releases

Search Press releases

Disposals of own shares

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Disposals of own shares

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care

UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Disposals of own shares

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Disposals of own shares

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care

UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease

Choose a Country